Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update

Aptevo Therapeutics Inc. (NASDAQ:APVO) saw a large drop in short interest in the month of January. As of January 15th, there was short interest totalling 19,000 shares, a drop of 92.1% from the December 31st total of 241,700 shares. Currently, 1.3% of the company’s shares are short sold. Based on an average daily volume of 325,400 shares, the days-to-cover ratio is presently 0.1 days.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on shares of Aptevo Therapeutics in a report on Monday, December 9th. They issued a “sell” rating on the stock.

Aptevo Therapeutics Price Performance

APVO traded up $0.15 during trading on Tuesday, reaching $4.64. 35,964 shares of the company were exchanged, compared to its average volume of 67,267. Aptevo Therapeutics has a 52 week low of $3.65 and a 52 week high of $399.60. The firm has a 50 day moving average of $97.86 and a 200 day moving average of $303.60.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.